An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

NCT05131438 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Extranodal NK/T-cell Lymphoma

Interventions

DRUG: sugemalimab

Sponsor

EQRx International, Inc.